About: Cancer and risk of COVID-19 through a general community survey

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cancer and risk of COVID-19 through a general community survey Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cancer and risk of COVID-19 through a general community survey
Creator	Wolf, Jonathan Chan, Andrew Lee, Karla Spector, Tim Steves, Claire Ma, Wenjie Sikavi, Daniel
Source	MedRxiv
abstract	Background: Data are limited on the risk of coronavirus disease 2019 (COVID-19) among individuals with cancer and whether cancer-related therapy exacerbates this risk. Methods: We evaluated the risk for coronavirus disease 2019 (COVID-19) among patients living with cancer compared to the general community and whether cancer-related treatments influence this risk. Data were collected from the COVID Symptom Study smartphone application since March 24, 2020 (United Kingdom), March 29 (U.S.), and April 29, 2020 (Sweden) through May 8, 2020. We used multivariate-adjusted odds ratios (aORs) of a positive COVID-19 test as well as predicted COVID-19 infection using a validated symptom model. Results: Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared to participants without cancer, those living with cancer had 62% increased risk of a positive COVID-19 test (95% CI: 1.37-1.91). Among patients with cancer, current treatment with chemotherapy/immunotherapy was associated with a nearly 2.5-fold increased risk of a positive test (aOR: 2.42; 95% CI: 1.81-3.25). The association between cancer and COVID-19+ was stronger among participants >65 years (aOR: 1.93; 95%CI: 1.51-2.46) compared to younger participants (aOR: 1.32; 95%CI: 1.06-1.64; Pinteraction<0.001); and among males (aOR: 1.71; 95%CI: 1.36-2.15) compared to females (aOR: 1.43; 95%CI: 1.14-1.79; Pinteraction=0.02). Conclusions: Individuals with cancer had a significantly increased risk of infection compared to the general community. Those treated with chemotherapy or immunotherapy were particularly at-risk of infection. Trial Registration: ClinicalTrials.gov NCT04331509
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.20.20103762
has license	medrxiv
sha1sum (hex)	9d2e9a500a4a892c67611f9f8b048d7fc2ab072d
schema:url	https://doi.org/10.1101/2020.05.20.20103762
resource representing a document's title	Cancer and risk of COVID-19 through a general community survey
resource representing a document's body	covid:9d2e9a500a4a892c67611f9f8b048d7fc2ab072d#body_text
is schema:about of	named entity 'THERAPY' named entity 'COVID-19' named entity 'risk' named entity 'coronavirus disease 2019' named entity 'CC-BY-NC 4.0' named entity 'NC 4' named entity 'diabetes' named entity 'NSAIDs' named entity 'symptom' named entity 'infection' named entity 'aspirin' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'U.S.' named entity 'NSAIDs' named entity 'medRxiv' named entity 'United States' named entity 'lung disease' named entity 'medRxiv' named entity 'Austria' named entity 'preprint' named entity 'sample sizes' named entity 'CC-BY-NC 4.0' named entity 'preprint' named entity 'Wald test' named entity 'COVID' named entity 'medRxiv' named entity 'methotrexate' named entity 'CC-BY-NC 4.0' named entity 'COVID' named entity 'CC-BY-NC 4.0' named entity 'CC-BY-NC 4.0' named entity 'obese' named entity 'medRxiv' named entity 'King's College London' named entity 'medRxiv' named entity 'mobile application' named entity 'chemotherapy' named entity 'smartphone' named entity 'peer review' named entity 'immunotherapy' named entity 'NHS' named entity 'logistic regression' named entity 'preprint' named entity 'statistically significant' named entity 'higher risk' named entity 'medRxiv' named entity 'preprint' named entity 'COVID' named entity 'COVID' named entity 'non-steroidal anti-inflammatory drugs' named entity 'preprint' named entity 'preprint' named entity 'heart disease' named entity 'health problems' named entity 'preprint' named entity 'immunotherapy' named entity 'medRxiv' named entity 'clinical trial' named entity 'Anonymized data' named entity 'peer review' named entity 'treatment regimens' named entity 'positive COVID-19 test' named entity 'comorbidities' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'kidney disease' named entity 'preprint' named entity 'Immunosuppressant' named entity 'preprint' named entity 'Covid-19' named entity 'comorbidities' named entity 'medRxiv' named entity 'COVID-19 testing' named entity 'Vienna' named entity 'demographic information'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software